Advertisement

Topics

Safety and Efficacy of Hematide™ for the Correction of Anemia in Patients With Chronic Renal Failure (PEARL 2)

2014-08-27 03:33:34 | BioPortfolio

Summary

The purpose of this study is to evaluate the safety and efficacy of an experimental drug for the treatment of anemia in patients with Chronic Renal Failure (CRF), who is not on dialysis and not on Erythropoiesis Stimulating Agent (ESA) treatment.

Description

Anemia of chronic renal failure is due to several factors, primarily the inability of the diseased kidneys to produce adequate amounts of endogenous erythropoietin. Ancillary factors also include the shortened lifespan of red blood cells, iron and other nutritional deficiencies, infection, and inflammation. The prevalence of anemia increases with progressive deterioration of renal function, and affects more than 90% of patients with CKD Stage 5 (End Stage Renal Disease). Anemia is associated with increased mortality, increased likelihood of hospitalization, reduced cognitive function and exercise capacity, increased left ventricular hypertrophy and heart failure. Treatment of anemia reduces morbidity and mortality risks and may improve quality of life. Therefore, anemia should be diagnosed and treated early.

Erythropoiesis stimulating agents have been established as a treatment for anemia in chronic renal failure subjects, and have improved the management of anemia over alternatives such as transfusion. Hematide is a parenteral formulation being developed for the correction of anemia in patients with chronic renal failure, and binds to and activates the human erythropoietin receptor and stimulates erythropoiesis in human red cell precursors in a manner similar to other known erythropoiesis-stimulating agents.

Subjects participating in this study will receive variable doses of Hematide every 4 weeks or darbepoetin alfa every 2 weeks. Total commitment time for this study is 4 weeks of screening followed by a minimum of 52 weeks of study treatment.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Chronic Renal Failure

Intervention

Hematide™, Darbepoetin Alfa

Location

Research Facility
Phoenix
Arizona
United States
85012

Status

Completed

Source

Affymax

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:33:34-0400

Clinical Trials [2927 Associated Clinical Trials listed on BioPortfolio]

Safety Study of Hematide to Correct Anemia in Hemodialysis Patients

The purpose of this research study is to see if an experimental new drug called Hematide™ is safe and effective for the treatment of anemia in patients with Chronic Renal Failure who are...

Hematide™ Injection for Anemia in Chronic Hemodialysis (HD) Patients

To evaluate the safety and efficacy of Hematide™ in the maintenance treatment of anemia in hemodialysis patients.

Study of the Efficacy of Darbepoetin Alfa in the Treatment of Renal Anemia

Anaemia is a common consequence of chronic renal failure. Darbepoetin alfa is a unique erythropoietic protein that stimulates erythropoiesis by the same mechanism as endogenous erythropiet...

Safety and Pharmacokinetics (PK) of Single Intravenous (IV) Doses of Hematide™ in Healthy Volunteers

The purpose of this study is to evaluate the safety, PK, and minimum pharmacologically active dose of Hematide™ in Healthy Volunteers.

A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for the Maintenance Treatment of Anemia in Kidney Transplant Recipients.

This 2 arm study will compare the efficacy and safety of subcutaneous Mircera versus darbepoetin alfa for the maintenance of hemoglobin levels in kidney transplant recipients with chronic ...

PubMed Articles [12517 Associated PubMed Articles listed on BioPortfolio]

Transforming growth factor beta-1 An important biomarker for developing cardiovascular diseases in chronic renal failure.

Our study focuses on the determination and evaluation of TGF-β1 levels of patients receiving hemodialysis treatment because of chronic renal failure.

Erhuang Formula ameliorates renal damage in adenine-induced chronic renal failure rats via inhibiting inflammatory and fibrotic responses.

The present study aimed to evaluate the protective effects of Erhuang Formula (EHF) and explore its pharmacological mechanisms on adenine-induced chronic renal failure (CRF).

Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.

Erythropoiesis-stimulating agents (ESAs) are often used in treatment of patients with chemotherapy-induced anemia. Many studies have demonstrated an improved hemoglobin (Hb) response when ESA is combi...

Galectin-3, Markers of Oxidative Stress and Renal Dysfunction in Patients With Chronic Heart Failure.

to determine levels of galectin-3, markers of renal dysfunction, and plasma oxidative stress; to assess their correlation in patients with chronic heart failure (CHF) of various severity.

Prostaglandin E2 regulates renal function in C57/BL6 mouse with 5/6 nephrectomy.

To investigate the roles of cyclooxygenases (COX) and their metabolites in C57/BL6 mice with 5/6 nephrectomy, an animal model of chronic renal failure.

Medical and Biotech [MESH] Definitions

A recombinant protein which stimulates ERYTHROPOIESIS used to treat ANEMIA.

A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal failure, either acute (KIDNEY FAILURE, ACUTE) or chronic (KIDNEY FAILURE, CHRONIC), requires HEMODIALYSIS.

Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage renal disease (CHRONIC KIDNEY FAILURE). (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002)

Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. The most severe form is KIDNEY FAILURE. Renal function may deteriorate slowly (RENAL INSUFFICIENCY, CHRONIC) or precipitously (RENAL INSUFFICIENCY, ACUTE).

Condition where a primary dysfunction of either heart or kidney results in failure of the other organ (e.g., HEART FAILURE with worsening RENAL INSUFFICIENCY).

More From BioPortfolio on "Safety and Efficacy of Hematide™ for the Correction of Anemia in Patients With Chronic Renal Failure (PEARL 2)"

Quick Search
Advertisement
 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Searches Linking to this Trial